Gastroparesis: The Complex Interplay with Microbiota and the Role of Exogenous Infections in the Pathogenesis of the Disease

Abstract

Gastroparesis (GP) is a disorder of gastric functions that is defined by objective delayed gastric emptying in the absence of mechanical obstruction. This disease is characterized by symptoms such as nausea, post-prandial fullness, and early satiety. GP significantly impacts patients’ quality of life and contributes to substantial healthcare expenses for families and society. However, the epidemiological burden of GP is difficult to evaluate, mainly due its significant overlap with functional dyspepsia (FD). GP and FD represent two similar diseases. The pathophysiology of both disorders involves abnormal gastric motility, visceral hypersensitivity, and mucosal inflammation. Moreover, both conditions share similar symptoms, such as epigastric pain, bloating, and early satiety. The latest evidence reveals that dysbiosis is directly or indirectly connected to gut–brain axis alterations, which are the basis of pathogenesis in both FD and GP. Furthermore, the role of microbiota in the development of gastroparesis was demonstrated by some clinical studies, which found that the use of probiotics is correlated with improvements in the gastric emptying time (GET). Infections (with viruses, bacteria, and protozoa) represent a proven etiology for GP but have not been sufficiently considered in current clinical practice. Previous viral infections can be found in about 20% of idiopathic GP cases. Moreover, delayed gastric emptying during systemic protozoal infections represents a huge concern for compromised patients, and few data exist on the topic. This comprehensive narrative review analyzes the relationship between microorganisms and GP. We explore, on the one hand, the correlation between gut microbiota dysbiosis and GP pathogenesis, including treatment implications, and, on the other hand, the association between exogenous infections and the etiology of the disease.

Microbiota profiling in esophageal diseases: Novel insights into molecular staining and clinical outcomes

“…The role of H. pylori in EAC risk remains unclear. A meta-analysis of 28 studies found an inverse relationship, suggesting that H. pylori infection may confer protection against EAC [130] . However, other studies have found no clear association or have produced inconclusive results [131] .…”

“…DGE primarily arises from anatomical and physiological post-surgical abnormalities, such as peristalsis dysfunction resulting from complete vagotomy, gastric conduit torsion [129] , and pyloric spasm. However, there is evidence demonstrating that the composition of the microbiota can influence gastric emptying [130] . Furthermore, it is widely recognized that changes in intestinal bacteria can significantly affect gastrointestinal motility [131] .…”

Spore-Based Probiotic Bacillus subtilis: Current Applications in Humans and Future Perspectives

“…An additional avenue for exploration is based on the specificity of effects of different strains of B. subtilis on gut microbiome. Microbiota modifications seem to be a major player in many GI tracts and other organ system disorders, including gastroparesis and endometriosis in conjunction with IBS, as highlighted in recent reviews [63,64]. The effects of B. subtilis as a transient probiotic but not a permanent GI resident is largely unexplored in the context of these diseases, which opens a wide area for future clinical research.…”

Microbiota in Irritable Bowel Syndrome and Endometriosis: Birds of a Feather Flock Together—A Review

“…The involvement of the human intestinal microbiome has been firmly established in the pathophysiology of various gastrointestinal organic diseases, including colorectal polyps and cancer [ 12 , 13 ], inflammatory bowel diseases [ 14 ], and eosinophilic esophagitis [ 15 ]. Furthermore, it has been implicated in gastroparesis [ 16 , 17 ] and the occurrence of post-surgical complications [ 18 , 19 ] that necessitate endoscopic treatment [ 20 , 21 , 22 , 23 ].…”